Streetbeat News

Regulatory

MSOS

At the Benzinga Cannabis Capital Conference, Verano's Aaron Miles discussed the company's strategic positioning ahead of adult cannabis use legalization, highlighting their success in Florida and plans for expansion.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:40 pm

FLGC

Flora Growth (FLGC) has announced a definitive agreement to acquire TruHC for 2,770,562 of its common shares, valued at $6.4M. This acquisition leverages TruHC's German cannabis platform, enhancing Flora's global distribution network with TruHC's expertise in the cannabis sector. The deal is strategic ahead of Germany's expected growth to become the world's largest federally legal cannabis market, potentially surpassing $10 billion in market potential.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:24 pm

BNED

Barnes & Noble Education, Inc. (BNED) has announced the adoption of a short-term stockholder rights plan, designed to deter the acquisition of 10% or more of its outstanding common stock by any person or group. The plan includes a dividend distribution of one preferred share purchase right for each outstanding common share, exercisable at $5.00. These rights become exercisable only if a person or group acquires 10% or more of BNED's common stock, allowing other stockholders to purchase shares at a discount or the board to exchange shares for rights. The rights plan is effective until January 31, 2025, with the dividend distribution set for April 29, 2024. Paul Hastings LLP and Houlihan Lokey, Inc. are serving as legal counsel and financial advisor, respectively.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:23 pm

PTPI

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) received positive feedback from the FDA on its technology component for STENDRA's self-selection, aiming for OTC status. This feedback is a crucial step towards making STENDRA the first erectile dysfunction drug available OTC. The FDA's informal review acknowledged the technology's potential to address concerns related to the PDE5 inhibitor class, especially for nitrate-using patients. Petros plans to submit its pivotal two-arm Self-Selection study in 2H 2024, with further guidance on an upcoming Application Comprehension Study.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:18 pm

LEXX

LEXXW

Lexaria Bioscience Corp. has received approval from an ethics review board to begin a new study on GLP-1 drugs using its DehydraTECH technology. The study will compare the effects of a single dose of Rybelsus (semaglutide) in two DehydraTECH-enabled formulations against the standard Rybelsus formulation in up to 9 healthy volunteers. The study aims to demonstrate improved drug delivery, blood glucose control, and tolerability with DehydraTECH. Recruitment will start immediately, with dosing expected to begin within 30 days and completion anticipated this summer.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:17 pm

SNGX

Soligenix shares surged following the FDA's grant of orphan drug designation to MarVax's active ingredient for MARV infection prevention and post-exposure prophylaxis.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:12 pm

SPY

Fed's Jefferson emphasizes a full commitment to reducing inflation back to 2%, contrasting with previous remarks on Feb 22 about potential policy easing later this year. His latest statements do not mention any policy easing, highlighting a focus on combating inflation.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:05 pm

SPY

Fed's Jefferson highlighted that as of March, headline PCE inflation was at 2.7% over the past 12 months, with core PCE at 2.8%, according to Fed staff estimates. Despite progress in reducing inflation, he stated the job isn't done, expecting further decline in inflation with the policy rate maintained at its current level.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:05 pm

AMIX

Autonomix has been granted a U.S. patent for its catheter-based technology aimed at treating cancer-related pain. This technology, part of a portfolio with over 100 issued and pending patents, targets a $100 billion market opportunity. It represents a potential breakthrough by combining the detection of problematic neural signals and nerve ablation into a single procedure, which could significantly impact pain management and other medical indications.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:01 pm

NCNA

Trading for NCNA was halted and then resumed at 8:55 AM ET, following an update on its status. This event indicates a significant occurrence that prompted the halt and resumption, which could be due to a variety of reasons such as financial disclosures, regulatory news, or other material events.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:55 pm